Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation

E Faure, A Lionet, E Kipnis, C Noël… - Transplant infectious …, 2017 - Wiley Online Library
E Faure, A Lionet, E Kipnis, C Noël, M Hazzan
Transplant infectious disease, 2017Wiley Online Library
Pneumocystis pneumonia (PCP) incidence was decreased in renal transplant thanks to
prophylaxis, recommended during the first months after transplantation. However, many late
PCP cases are observed after the first 6 months and recommendations to maintain or
reintroduce prophylaxis are lacking. The objective of the study was to identify risk factors to
guide the individual prescription of prophylaxis, 6 months after transplantation. Thirty‐three
late PCP cases were identified between 1995 and 2012 in Lille Hospital, France, and were …
Abstract
Pneumocystis pneumonia (PCP) incidence was decreased in renal transplant thanks to prophylaxis, recommended during the first months after transplantation. However, many late PCP cases are observed after the first 6 months and recommendations to maintain or reintroduce prophylaxis are lacking. The objective of the study was to identify risk factors to guide the individual prescription of prophylaxis, 6 months after transplantation. Thirty‐three late PCP cases were identified between 1995 and 2012 in Lille Hospital, France, and were compared to 72 randomized controls transplant recipients. In univariate analysis, age of donor (>48 years), retransplantation, a decrease glomerular filtration rate (≤45 mL/min), induction therapy mediated by anti‐thymocyte globulin (ATG), steroid maintenance, high calcineurin inhibitors (CNI) doses (tacrolimus ≥0.5 mg/kg/day and cyclosporine ≥2.1 mg/kg/day), and cytomegalovirus (CMV) infection were significantly associated with PCP. In multivariate analysis, ATG (hazard ratio [HR]: 2.4 [1.1‐5.4]), steroid therapy (HR: 3.1 [1.20‐7.84], CNI (HR: 2.9 [1.28‐6.38], and CMV (HR: 6.1 [2.74‐16.33] remained associated with late PCP. In conclusion, we confirm that intensive immunosuppressive regimen and CMV infection are critical risk factors for late PCP and should be taken into account to decide on maintenance or reintroduction of a prophylactic treatment.
Wiley Online Library
以上显示的是最相近的搜索结果。 查看全部搜索结果